Reboxetine

Drug #1745

Reboxetine is a selective inhibitor of noradrenaline re-uptake, has been introduced for the treatment of depression.

← Previous drug Next drug →

Primary Characteristics

Non-proprietary name: Reboxetine.

Pharmacokinetics

None recorded.

Indications

Reboxetine is primarily indicated in conditions like Depressive illness.

Contraindications

Reboxetine is contraindicated in conditions like Pregnancy, Breast feeding.

Dosage

Reboxetine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
4 mg	4 mg	Every 12h	PO	The full therapeutic dose can be given upon starting treatment. After 3 - 4 weeks, this dose can be increased to 10 mg/day in case of incomplete clinical response.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Reboxetine is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Dizziness, Dry mouth, Dysuria, Hypokalemia , Impotence, Insomnia, Paresthesias, Postural hypotension, Sweating , Tachycardia, Urinary retention, Urinary RetentionX, Vertigo.

Warnings / Precautions

Reboxetine should be used with caution in patients with severe renal impairment, hepatic impairment, history of cardiovascular disease and epilepsy, bipolar disorders, urinary retension, prostatic hypertrophy, glaucoma.

Available Brands

None recorded.

Drug Classification

1.24.2.1 — Drugs used in depression